Hybrigenics' inecalcitol boosts Taxotere response in HRPC
Hybrigenics, a French biopharmaceutical company, has reported encouraging preliminary results from a Phase II trial of inecalcitol in patients with hormone-refractory prostate cancer.
According to the Paris-based firm, the clinical tolerance of inecalcitol was "excellent," and no changes in calcium parameters have been observed in any of the 42 patients enrolled so far, even at the highest dose of 1,000mcg/day currently being tested since January 2009.
This safety profile is especially positive for inecalcitol because hypercalcemia is the usual specific toxic effect of most vitamin D analogs, limiting their use at doses as low as 10mcg/day. The "excellent" tolerance of inecalcitol allowed a fast and effective patient enrolment for an accelerated dose-escalation approved by the French Regulatory Drug Agency (AFSAPS), Hybrigenics noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze